Trials / Completed
CompletedNCT00731861
Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Indiana University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate PTK787, a new oral drug that stops blood vessel development, in combination with Paclitaxel in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel plus PTK787 | Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT. In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY. |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2008-09-01
- Completion
- 2010-08-01
- First posted
- 2008-08-11
- Last updated
- 2014-09-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00731861. Inclusion in this directory is not an endorsement.